CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

A PureTech startup banks $180M for a new IPF drug

Celea drug candidateEsbrietPositive
AI Analysis

Summary

Celea, a PureTech-backed startup, raised $180M in funding from investors including RA Capital and Leaps by Bayer to develop an improved version of Roche's Esbriet for idiopathic pulmonary fibrosis.

Importance:6/10
Sentiment:
0.60
IPFidiopathic pulmonary fibrosisfundingPureTechCelea
Related Companies

Read the original article

Published by BioPharma Dive on July 2, 2026 3:04 PM

Read Original